Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
BMS axes bispecific months after filing to run phase 3 trial
BMS had had a whiplash change of heart on a BCMA bispecific T-cell engager, halting further development months after filing to run a phase 3 trial.
Nick Paul Taylor
Jul 26, 2024 8:17am
Acticor halts stroke trial for blood thinner over futility
Jul 26, 2024 8:10am
Calliditas' rethought liver disease trial hits primary endpoint
Jul 26, 2024 5:32am
Chemomab trumpets liver disease win, but investors retreat
Jul 25, 2024 9:32am
Pfizer gene therapy reduces bleeds in ph. 3 hemophilia A trial
Jul 24, 2024 8:44am
OSE's ulcerative colitis prospect improves symptoms in phase 2
Jul 24, 2024 8:23am